- 1 BD is hot on the M&A path
- 2 Investors Support Virtual Incision with $46 Million Funding
- 3 A 3D printed eye? Oh my!
- 4 And in case you missed our latest Medtech in a Minute report…
- 5 A great moment for minimally invasive glaucoma surgery
- 6 FDA identifies a rare but serious complication risk associated with Medtronic’s leadless pacemaker
- 7 New robotics center coming to Germany
BD is hot on the M&A path
BD is one of the few medtech companies that has been active in mergers and acquisitions (M&A). The company said it is acquiring Venclose, a company that has developed an RF ablation technology platform that treats a disease that results from malfunctioning valves and can lead to varicose veins. This is the seventh acquisition that BD has announced in 2021.
Investors Support Virtual Incision with $46 Million Funding
Virtual Incision, a company developing a miniaturized in vivo robotic assistant surgical platform, has raised $46 million in Series C funding. John Murphy, the company’s president and CEO, said: MD+DI the funding will be used for clinical regulatory work, R&D and building the technical and commercial teams. The company focuses on colon surgery for the first indication and, if all goes to plan, will pursue indications for gallbladder removal, hysterectomy, sleeve gastrectomy and others.
A 3D printed eye? Oh my!
A man in London, England has become the first person in the world to receive a fully digitally 3D-printed eye. The 3D-printed eye is a true biomimic and more realistic prosthesis, with clearer definition and true depth to the pupil, according to Moorfields Eye Hospital. Unlike traditional methods, it uses scans of the eye rather than an invasive mold of the eye socket.
And in case you missed our latest Medtech in a Minute report…
A great moment for minimally invasive glaucoma surgery
iStar Medical has just made its mark in the fast-growing minimally invasive glaucoma surgery market with the European launch of its MINIject glaucoma implant. iStar said MINIject is now the only commercially available minimally invasive supraciliary device for glaucoma, meaning it is the only approved MIGS device designed to target the supraciliary space as a natural outflow pathway for the reduction of intraciliary -ocular pressure. The news of the company’s CE marking follows Alcon’s announcement that it plans to acquire Ivantis.
FDA identifies a rare but serious complication risk associated with Medtronic’s leadless pacemaker
The FDA has written a letter to remind cardiac surgeons that there are three risks of serious complications if a heart perforation occurs during a leadless pacemaker implant. Although cardiac perforation is a rare complication (occurring in approximately 1% of cases) of any pacemaker implant procedure, field data suggest that the risk of serious complications following cardiac perforation may be higher in patients receiving a Medtronic Micra leadless pacing system than a traditional transvenous pacing system. pacemaker. The Medtronic Micra is the only leadless pacemaker on the US market.
New robotics center coming to Germany
Smith & Nephew plans to build a digital surgery and robotics innovation center in Munich, Germany. The new center is expected to open in late 2022 and will bring health professionals from Europe, the Middle East and Africa together with the company’s R&D and medical education teams to explore digital surgery and robotics techniques and technologies. At its core is Real Intelligence, Smith & Nephew’s digital ecosystem, including the new CORI robotic-assisted surgical system.